Pulmonary arterial hypertension (PAH) describes a group of conditions with a common hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive remodeling of small pulmonary arteries, leading to right heart failure and death.
Pulmonary Vascular Remodeling in PAH -Many Problems, Few Solutions.
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure of greater than 25 mmHg at rest [1] . Diagnostic groups are further classified according to clinical, etiological and hemodynamic features (Table 1) but share common symptoms of increased breathlessness on exertion, right heart failure and ultimately result in premature death [1] . Pulmonary arterial hypertension (PAH) (see Glossary) is characterized by sustained vasoconstriction and a progressive obliteration of small resistance pulmonary arteries and arterioles through a process of intimal and medial thickening and the formation of angioproliferative plexiform lesions [2] . Pulmonary vascular insults cause endothelial dysfunction and apoptosis thereby impairing endothelial-mediated suppression of quiescent smooth muscle cells [3] . This, coupled with clonal expansion of apoptosis-resistant endothelial cells, promotes a proliferative vasculopathy that also involves a complex interplay with adventitial fibroblasts, perivascular inflammatory cells and the extracellular matrix [3] . Despite considerable advances in PAH treatment, this devastating disease still carries a prognosis worse than many cancers with a 3-year survival of 68-70% [4, 5] . Current therapies predominantly target pulmonary vasoconstriction rather than proliferative vascular remodeling and therefore new strategies are urgently required to directly address the pathological remodeling that underpins the disease.
PAH constitutes diagnostic Group 1 (Table 1) and is characterized by added hemodynamic criteria that define pre-capillary pulmonary hypertension with absence of left-sided heart disease (Group 2), lung diseases (Group 3) or thromboembolic disease (Group 4). However, Group 1 comprises patients with a wide range of conditions that are associated with the development of PAH and thus within this group, there may be considerable mechanistic heterogeneity at a molecular and pathophysiological level. Consequently, we limit this review by focusing on key pathogenic processes of idiopathic PAH (IPAH) and its heritable form (HPAH), rare conditions with a combined annual incidence of approximately 1-2 per million [4, 6] .
The breadth of disruption of pulmonary vascular cell biology in PAH is becoming apparent. Recent studies of genetic and epigenetic factors, DNA damage and disordered metabolism have yielded important mechanistic insights into established disturbances of endothelial function and smooth muscle cell proliferation. We discuss the central importance of bone morphogenetic protein receptor 2 (BMPR-II) signaling in PAH and focus on approaches to rescue the disease-associated suppression of this pathway. Other new genetic leads are explored and the rapidly expanding field of microRNA biology and its relevance to PAH is discussed. Furthermore, work on triggers for PAH development has added to our understanding of the role of inflammation and hypoxia in PAH and we highlight key recent findings in these areas. Although it is not yet clear how all of these problems combine temporally and mechanistically, these advances bring enormous potential for new therapeutic approaches that specifically target vascular remodeling, providing fresh hope of significant impact on disease progression and improved patient outcomes.
The Ups and Downs of BMPR-II Signaling in PAH.
Since the identification of mutations in the gene encoding bone morphogenetic protein receptor 2 (BMPR2) in families with PAH [7, 8] , BMPR2 has become the predominant genetic factor in heritable forms of the disease, with a large amount of evidence implicating it as a central molecular player in PAH. BMPR-II is a member of the transforming growth factor beta (TGF-) receptor family that forms a dimer with an activin receptor-like kinase (ALK) [9] . There are multiple ALKs and each heterodimeric combination confers different ligand affinity [10] . Thus, differential expression in tissues may alter sensitivity to specific bone morphogenetic protein (BMP) ligands. Notably, the BMPR-II/ALK-1 heterodimer signals with relative specificity in response to BMP9 and BMP10 in human microvascular endothelial cells (ECs) [11] while BMPR-II/ALK-3 or -6 signals in response to BMP2 or BMP4 in smooth muscle cells [12] . Upon ligand binding, the receptor phosphorylates SMAD proteins (mothers against decapentaplegic homologs) that complex and translocate to the nucleus, regulating in turn the expression of target genes (e.g. inhibitor of DNA binding (ID) proteins) through SMAD binding elements ( Figure 1 ) [13] .
Mutations in BMPR2 have been found in >70% of patients with heritable disease [7, 8] and in up to 25% of patients with idiopathic disease [14] . On the one hand, reduced protein expression of BMPR-II is also found in patients with PAH devoid of BMPR2 mutations [15] , emphasizing the importance of this signaling pathway in disease. But on the other hand, in HPAH, while transmission is autosomal dominant, only 20% of carriers develop disease, implying that other triggers are required [16] . The importance of environmental or host factors ( Figure 2 ) in addition to impaired BMPR-II signaling is supported by evidence from BMPR-II-deficient animal models. For instance, mice with heterozygous null or hypomorphic Bmpr2 mutations do not develop spontaneous PAH, and only around 30% of mice with either Cre-dependent deletion of Bmpr2 in ECs [17] or inducible overexpression of a dominant negative BMPR-II in smooth muscle cells [18] show evidence of elevated right ventricular systolic pressure (RVSP). In contrast, a more recent study used mice incorporating a heterozygous knock-in allele bearing the R899X stop mutation in exon 12, a Bmpr2 mutation associated with human PAH, and these animals developed spontaneous elevation in RVSP by 6 months of age [19] . In this model, penetrance and disease severity were enhanced by additional knockout of the Smad1 gene, suggesting that suppression of BMPR-II signaling might be sufficient to precipitate disease [19] . However, the explanation for the difference in disease susceptibility between mice with haploinsufficiency due to heterozygous null or R899X mutations in Bmpr2 remains unclear and warrants further investigation. Interestingly, a transgenic rat with a heterozygous 140 base pair deletion in exon 1 of the Bmpr2 gene has recently been described [20] .
While not yet fully phenotyped, by 3 months of age these rats developed abnormal muscularization of small pulmonary arteries compared to wild-type littermates, although this was not associated with significant hemodynamic changes at that age [20] . These early remodeled vessels showed evidence of endothelial-to-mesenchymal (EndoMT) transition, with overexpression of relevant markers (such as Twist-1 and phosphorylated vimentin) by immunohistochemistry [20] .
Evidence of EndoMT was also observed by staining human PAH lung sections and sections from monocrotaline-treated rats [20] . Another study demonstrated that siRNA knockdown of BMPR2 induced mesenchymal phenotypic changes in human pulmonary artery endothelial cells (PAECs) [21] . This was associated with increased expression of high mobility group AT-hook 1 (HMGA1) and Slug, transcription factors that have been implicated in epithelial-to-mesenchymal transition and are overexpressed in PAECs from patients with BMPR2 mutations [21] .
BMPR-II deficiency also impacts upon mechanisms involved in the reversal of vascular remodeling. In the knowledge that hypoxia-induced pulmonary hypertension in mice is ubiquitously reversible, one study demonstrated that EC-specific deletion of Bmpr2 inhibited reversal of PH upon reoxygenation [22] . Mitochondrial dysfunction in BMPR-II deficient endothelial cells led to mitochondrial DNA damage and apoptosis, preventing regeneration of distal pulmonary arteries following hypoxia/reoxygenation [22] .
Importantly, the sensitivity of PAECs to mitochondrial-induced apoptosis with hypoxia/reoxygenation was confirmed in vitro in primary cells from patients with BMPR2 mutations [22] . While broader abnormalities in cellular metabolism --including aerobic glycolysis, pentose phosphate pathway activation and abnormal fatty acid metabolism --have been reported in PAH (Box 1), this finding of mitochondrial dysfunction in BMPR-II-deficient cells implies that genetic predisposition directly alters the capacity to repair a pulmonary vascular injury. Moreover, as will be discussed later, impaired BMPR-II signaling predisposes to pro-inflammatory phenotypes in pulmonary vascular tissue cells that may exacerbate the injury response and promote disease progression [22] .
While targeting EndoMT, mitochondrial dysfunction and inflammation may be possible, the pleotropic effects of suppressed BMPR-II signaling in PAH stress the importance of restoring this pathway as a therapeutic objective.
The Sexy Side of BMPR-II.
An important host factor associated with disease susceptibility is sex, with a female to male ratio of approximately 2.5:1 in recent IPAH cohorts. [4, 6] . The mechanisms underlying this predisposition are becoming clearer and link closely to BMPR-II signaling. For example, estrogen has been shown to suppress BMPR-II signaling [23] with sex-specific consequences for in vitro PASMC phenotypes [24] . Female, but not male human PASMCs, proliferate in response to the same dose of key mitogens (e.g. serotonin (5HT), platelet-derived growth factor (PDGF), suggesting heightened sensitivity to pro-proliferative stimuli [24] . In this study, sex differences were attributed to suppression of SMAD activation upon stimulation, in addition to a reduction in basal expression of BMPR-II pathway components including BMPR-II, SMAD1/5/8, and the ID proteins, ID1 and ID3 [24] . These in vitro findings are supported by the in vivo observation that the aromatase inhibitor anastrazole reduced progression of established PAH in female rats and mice [25] . Translation of these pre-clinical studies into human trials is eagerly anticipated, particularly in view of recent evidence, from a small case-control study, that male patients with PAH exhibit significantly higher levels of circulating estradiol when compared to healthy controls [26] . However, there is an apparent paradox in these findings, as male sex is a predictor of worse survival in These strategies to target one of the key pathways implicated in PAH pathogenesis offer real potential to translate into disease-modifying treatments, even for patients with BMPR2 mutations. However, given diversity of the molecular mechanisms involved and the limited pool of patients for large randomized trials, work to predict those likely to respond to specific strategies should be encouraged. While there is huge potential to discover rare genetic variations associated with PAH through the analysis of coding sequences, and now, whole genome sequencing with next generation sequencing, interpretation of these data remains difficult. Indeed, large patient numbers are required to identify rare causal variants with sufficient power. The successful use of these technologies in this rare disease will therefore require broad international collaborations.
The Role of microRNAs in PAH.
Beyond the genetic factors involved in PAH, a broad disruption of transcriptional regulation is now also evident. The expression of numerous micro-RNAs (miRs) is The explosion in miR biology opens many potential therapeutic avenues and a variety of miR mimics or inhibitors have shown efficacy in animal PAH models (Table 2) .
However, target specificity, cellular penetration, degradation and possible hepatotoxicity represent significant hurdles that need to be overcome for these molecules to translate into therapeutic interventions in humans.
Disease Drivers in PAH.
While the described disturbances in BMPR-II pathway regulation, metabolism and DNA damage/repair mechanisms are fundamental in PAH pathophysiology, the triggers and drivers of disease (both in the presence and absence of genetic predisposition) remain unclear. Recent studies have provided insight into the involvement of hypoxia and inflammation as potential environmental mediators or drivers of PAH.
Hypoxic Signals Triggering PAH.
Ambient hypoxia is widely used as a stimulus for a proliferative vasculopathy in animal PH models; it also triggers reversible pulmonary vascular remodeling in humans following ascent to high altitude [53, 54] . Alveolar hypoxia is likely to be an integral pathogenic factor in Group 3 patients (Table 1) [57] or Hif2a [58] protects mice from hypoxia-induced PH but the mechanism has been unclear. The dominant regulation of metabolic genes by HIF-1 is likely to be important given the metabolic changes favoring aerobic glycolysis in pulmonary vascular cells (Box 2) and normoxic stabilization of HIF-1 has been described in human pulmonary vascular lesions [59] . However, recent evidence has highlighted the importance of endothelial HIF-2 in animal models of PH.
One study reported that mice harboring a Phd2 (Egln1) deletion in endothelial and hematopoietic cells (Tie2-Cre expression) developed a spontaneous and fatal PH phenotype with impressive pulmonary vascular remodeling and hemodynamic changes [60] . As expected, both HIF- isoforms were upregulated in normoxic PHD-2 deficient ECs, but double knockout studies (Phd2 and Hif1a or Hif2a) indicated HIF-2 was the key mediator of the phenotype [60] . Several pathways implicated in PH were altered in PHD-2 deficient mice including downregulation of Bmpr2 and Cav1 and could be rescued by deletion of Hif2a [60] . The proposed mechanism involved HIF-2-mediated upregulation of chemokine CXCL12, a proliferative stimulus for PASMCs. Similar findings were independently obtained using an alternative mouse line (Cdh5-Cre expression) to conditionally delete Phd2; however, this paper focused on hypoxic induction of the vasoconstrictor endothelin-1 (Edn1) as a potential mechanism, showing HIF-2-dependent increases in lung expression of Edn1 in PHD-2 deficient mice [61] .
Interestingly, PAH has also been described in humans with rare gain-of-function mutations in HIF2A [62] . However, PAH was not reported as a cause of death in a small study of patients with HIF activation due to mutations in the VHL gene (Chuvash polycythemia) [63] , even though such patients do present heightened pulmonary vasoconstriction in response to hypoxia [64] .
There are several alternative mechanisms for the regulation of PAH by HIF-2. It has been recently demonstrated that the protection against hypoxia-induced PH mediated by EC deletion of Hif2a in mice is associated with reduced expression of arginases and that deletion of endothelial Arg1 reproduced a protective phenotype [65] . Moreover, the endothelial NO pathway is strongly implicated in PAH and may represent an important therapeutic target [66] . Thus, diversion of L-arginine from nitric oxide synthase through increased arginase activity may be a credible disease driver. Notably, a further target of HIF-2 is the transcription factor, POU5F1 (or OCT4), which can upregulate miR-130/301 in ECs and PASMCs exposed to hypoxia, as discussed earlier [49] . Finally, through elegant linkage analysis and congenic breeding of a rat strain known to be resistant to hypoxia-induced PH (the Fisher 344 strain), the Slc39a12 gene was identified as a novel HIF-activated regulator of hypoxia-induced pulmonary vascular remodeling [67] . The upregulation of the protein product, zinc transporter (ZIP12), in hypoxic pulmonary vascular tissue was conserved across several species and confirmed in IPAH tissue, while mutation of Slc39a12 attenuated hypoxia-induced pulmonary hypertension in rats [67] . In light of these multiple strands of evidence for HIF-pathway activation in PAH, it may be important to consider screening for PH in patients treated with PHD inhibitors (e.g. Roxadustat), which are progressing in clinical trials to ameliorate renal anemia [68] .
Inflammation and Cytokines -Potential Targets in PAH.
Perivascular inflammation is a characteristic feature of PAH [2] and many inflammatory cell-types are mooted to have roles in disease pathogenesis [19, 69] . Elevated inflammatory cytokine levels are described in IPAH patients [70, 71] but whether inflammation is a trigger for disease in susceptible patients or a consequence of established disease is not clear. There is increasing evidence that genetic predisposition to PAH through BMPR-II deficiency involves a pro-inflammatory phenotype. Human PAECs transfected with BMPR2 siRNA exhibited enhanced expression of IL-6 and IL-8 compared to control cells [22] and BMPR2 +/-human PASMCs released more IL-6 in response to endotoxin (LPS) [72] . BMPR-II deficient mice showed increased expression of IL-6 and KC (murine IL-8) in lung tissue in response to LPS and these findings were mirrored in murine PASMCs ex vivo [72] . Of note, murine PASMCs were isolated from haploinsufficient BMPR-II mice with no evidence of PH but exposure of such mice to LPS for 6 weeks was sufficient to induce disease supporting the hypothesis that inflammation plays an initiating role in PAH, at least in the context of BMPR-II deficiency [72] . BMPR-II deficient human and murine PASMCs and Bmpr2 haploinsufficient mouse lungs demonstrated superoxide dismutase (SOD3) deficiency, implicating impaired handling of reactive oxygen species in the mechanism underlying the pro-inflammatory phenotype in these models [72] .
Indeed, both in vitro inflammatory responses due to BMPR-II deficiency and the development of PH in BMPR-II deficient mice following chronic LPS exposure could be attenuated by tempol, an antioxidant [72] .
These data imply that antioxidant supplementation and targeting specific cytokines (e.g. IL-6) might represent strategies to prevent the development of PAH in patients with BMPR2 mutations.
How BMPR-II regulates increased inflammatory cytokine expression is not fully understood but recent work has implicated the eukaryotic translation initiation factor (eIF2) as a translational regulator of TNF-induced granulocyte macrophage colonystimulating factor (GM-CSF) release from human PAECs [73] . In this study, BMPR-II deficiency was associated with sustained activation of p38 mitogen-activated protein kinase (MAPK) following TNF stimulation which indirectly led to de-phosphorylation of eIF2 and thus, enhanced GM-CSF translation [73] . In human IPAH there was evidence of higher GM-CSF expression in diseased lung tissue, while administration of GM-CSF in mice worsened PH in chronic hypoxia, consistent with a role for this cytokine in disease progression [73] . The importance of wider translational repression by eIF2 deserves exploration given the observation that mutations in this pathway --specifically loss-of-function homozygous and compound heterozygous mutations in EIF2AK4, the gene encoding eIF2 kinase 4 --have been documented in other conditions of aberrant pulmonary vascular remodeling such as pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis [74, 75] .
Associated with the enhanced GM-CSF signaling described above, an increase in perivascular cells expressing macrophage markers was reported [73] suggesting that macrophage-derived cytokines such as leukotriene B4 [76] and IL-6 [70, 77] may be implicated in PAH. Given the potential for biological targeting of specific cytokines that may be pathogenically over-expressed in PAH, the role of macrophage and tissuederived cytokines in vascular remodeling is of particular interest.
Our group explored the role of TNF-related apoptosis-inducing ligand (TRAIL) in PAH, a TNF family member. Expression of TRAIL was upregulated in lung tissues from rodent models of PH [78] , in human lung sections and in PASMCs isolated from PAH patients [79] . Despite its known role of inducing apoptosis in transformed or malignant cells TRAIL acted as a PASMC mitogen in vitro [80] . Furthermore, blockade of TRAIL by either genetic deletion in mice or by administration of an anti-TRAIL polyclonal antibody in rats, prevented development of PH [80] . Moreover, polyclonal antibody targeting of TRAIL reversed established disease in mouse PH models [80] . Of note, osteoprotegerin (OPG), a binding partner for TRAIL --best known for its role in bone formation --is similarly of mechanistic and therapeutic interest [78] . In fact, levels of OPG are also increased by suppressed BMPR-II, serotonin and inflammatory stimuli (e.g. IL-1) [79] , and serum levels correlated with markers of disease severity (right atrial pressure and cardiac index) and predicted survival in PAH patients [81] . In addition, OPG, like TRAIL, drives proliferation of human PASMCs in vitro [79, 80] . Thus, studies investigating the therapeutic potential of targeting OPG in rodent models are currently underway [82] .
Concluding Remarks
Recent advances have revealed a wide range of biological disruption in PAH including metabolic, inflammatory and epigenetic abnormalities (Figure 2, Box 3 ). Understanding how all these processes integrate to promote the aberrant proliferative remodeling characteristic of PAH will be key to the generation of successful anti-remodeling therapies. Other questions also remain (see Outstanding questions), in particular how best to increase the success rate of translating pre-clinical discoveries to the bedside, which has been a significant challenge in PH [83] . It is noteworthy that the majority of studies in this review highlighting new therapeutic targets have incorporated both in vitro evidence from patient cells and often more than one animal model of disease, hopefully strengthening the translational potential of these discoveries.
Clear hubs for new therapies to target certainly exist. As highlighted above, novel strategies to enhance BMPR-II signaling (Figure 1 ) may be among the first of a new generation of drugs for PAH that specifically target known defective molecular regulators of pulmonary vascular remodeling. In addition, our increased understanding of metabolic abnormalities and inflammation has led to clinical trials targeting the metabolic switch to a pro-proliferative glycolytic phenotype in pulmonary vascular cells (e.g. Dichloroacetate, NCT01083524) and pro-proliferative cytokine pathways (e.g.
anti-IL-6 antibody, Tocilizumab, NCT02676947).
However, as different clinical groups, sexes and individuals are likely to have different drivers of disease, molecular phenotyping of patients with a precision medicine approach, akin to that used in cancer, may be required to identify patients most likely to respond to specific treatments. For example, in the context of reduced BMPR-II signaling (Figure 1 ), an individual with high SMURF1 protein expression or activity may respond better to a SMURF1 inhibitor rather than a treatment aiming to augment BMPR-II expression. To open the door for precision medicine, we need to integrate complex mutli-'omic datasets and generate a more comprehensive understanding of the heterogeneity in disease mechanisms, a strategy that will require a strong international collaboration. Nonetheless, for this devastating condition characterized by relentless vascular remodeling, the emerging opportunities described above provide hope of novel anti-remodeling treatments that will significantly improve patient outcomes in PAH. Intravenous anti-miR-17 treatment reduced RVSP and remodeling in hypoxic mouse and MCT rat models.
[84]
miR-20a SMAD5 Prophylactic intraperitoneal injections of anti-miR-20a prevented RVH and remodeling in hypoxic mouse model. [85] miR-21 BMPR2, WWP1
Intratracheal anti-miR-21 (prophylactic or treatment) reduced RVH and remodeling in hypoxic mouse model. [86] miR-26b CTGF, CCND1
Intratracheal treatment with mir-26b mimic reduced remodeling in MCT rat model. [87] miR-27b PPAR Intravenous anti-miR-27b treatment reduced RVSP, RVH and remodeling in rat MCT model. [88] miR-29 PPAR Intravenous anti-miR-29 injection attenuated RVSP and remodeling in Bmpr2 R899X (Doxycycline-induced transgene expression) model. [89] miR-34a PDGFRA Nebulized treatment with miR-34a mimic reversed PH in hypoxic rat model.
[90]
miR-96 5-HT1B Prophylactic intravenous administration of miR-96 mimic to female mice attenuated RVSP, RVH and remodeling in hypoxic mouse model.
[91]
miR-126 SPRED-1 Intravenous treatment with miR-126 mimic improved RV function and CO but had no significant effect on RVSP or pulmonary vascular remodeling in rat MCT model. [92] miR-130/301 PPAR Intrapharyngeal (mouse) or intraperitoneal (rat) injections of miR-130/301 inhibitor reversed PH in SuHx mouse model and rat MCT model.
[49] [93] miR-140-5p SMURF1 Nebulized miR-140-5p mimic (prophylactic or treatment) reduced RVSP, RVH and remodeling in rat MCT and SuHx models.
[36]
miR-145 KLF4 Prophylactic subcutaneous anti-miR-145 attenuated RVSP and remodeling in hypoxic mouse model.
Intratracheal treatment with miR-193 mimc reduced RVSP, RVH and remodeling in hypoxic mouse and MCT rat models.
[95]
miR-199a-5p
SMAD3
Intravenous anti-miR-199a-5p treatment reduced RVSP and RVH in rat MCT model. 
Box 1. Metabolic Reprogramming in PAH.
Abnormalities in cellular metabolism are well described in PAH, with evidence of aerobic glycolysis, pentose phosphate pathway activation, mitochondrial dysfunction, altered fatty acid metabolism and insulin resistance in disease [99] (and reviewed in [100, 101] ).
Mitochondrial hyperpolarization [102] and the shift towards aerobic glycolysis (or Warburg effect [103] ) has highlighted parallels between the biology of pulmonary artery smooth muscle cells (PASMCs) from PAH patients and cancer cells [100] . Recent work has increased our understanding of potential mechanisms behind these metabolic phenotypes.
One study found evidence implicating the mitochondrial de-acetylase Sirtuin 3 in PAH [104] . PASMCs deficient in SIRT3, had reduced mitochondrial respiration and increased membrane potential (suppressing mitochondrial-induced apoptosis) [104] . These cells also displayed activation of nuclear factor of activated T cells (NFAT), signal transducer and activator of transcription 3 (STAT3) and hypoxia inducible factor-1alpha (HIF-1), all key transcription factors linked to PAH pathogenesis [105] [106] [107] . As an upstream regulator of mitochondrial function linking to several key pro-proliferative and antiapoptotic pathways, SIRT3 may therefore constitute a promising therapeutic target.
Interestingly, a polymorphism associated with reduced SIRT3 function was overrepresented in 49 IPAH patients [104] . However, this finding requires replication in other patient cohorts and the same SNP was not identified in a genome-wide association study [45] . While this study implies that metabolic abnormalities predate the Beyond the pulmonary vasculature, the failure of the right ventricle (RV) to adapt and sustain its function in the face of rising pulmonary vascular resistance may also occur due to metabolic dysfunction. Using human RV tissue obtained at autopsy, direct evidence has been provided of a failure of long-chain fatty acid oxidation in myocardial cells, preventing subsequent utilization by the mitochondria. Consequent accumulation of fatty acids was associated with evidence of elevated ceramide, a marker of lipotoxicity [108] . Visualization of lipid accumulation in the RV myocardium was also evident using magnetic resonance spectroscopy on living patients implying this process is not simply an end-stage observation [108] .
Box 2. DNA Damage in PAH.
The hypothesis that DNA damage may lead to somatic mutations triggering changes in cell phenotype in PAH is not new with descriptions of clonal endothelial cell expansion in plexiform lesions and chromosomal abnormalities in explanted lung tissue [109, 110] .
However, recent evidence reporting increased susceptibility to DNA damage [111] and impaired DNA repair mechanisms [48, 112] highlight the importance of these processes in PAH and potentially provide insight into how apoptosis-susceptible, apoptosisresistant and hyperproliferative cell phenotypes arise with pulmonary vascular remodeling.
Significantly more DNA damage was observed in pulmonary artery endothelial cells from PAH patients compared to controls, but higher levels of damage were also demonstrated in peripheral blood mononuclear cells (PBMCs) implying that the damage is not confined to pulmonary vascular tissues [111] . Intriguingly a similar degree of damage was observed in PBMCs from the unaffected relatives of PAH patients and these cells showed higher sensitivity to mutagens [111] . These findings suggest that damage precedes the development of disease and may be determined by currently unknown genetic factors.
DNA damage response mechanisms are also dysregulated in PAH. In PASMCs, excess damage was associated with poly(ADP-ribose) polymerase-1 (PARP-1) activation, promoting survival and proliferation [113] . Inhibiting PARP-1 pharmacologically or with the micro-RNA, miR-223, restored PASMC susceptibility to apoptosis, reduced proliferation and reversed established PH in experimental models [48, 113] . A further gene implicated in DNA repair, the breast cancer 1 (BRCA1) gene, was downregulated in PAECs isolated from patients with PAH and associated with increased apoptosis susceptibility [112] . Interestingly, BRCA1 binds to the BMPR2 promoter and also has a SMAD binding element in its own promoter suggesting potential interaction with the BMPR-II pathway that could lead to a cycle of negative regulation and thus endothelial dysfunction in PAH [112] .
Box 3. The Clinician's Corner
Reversal of aberrant pulmonary vascular remodeling in pulmonary hypertension remains a holy grail in the field. While currently available drugs have improved survival, these treatments predominantly target pulmonary vasoconstriction and are not specifically designed to modify molecular abnormalities associated with remodeling.
Defective BMPR-II signaling, whether through genetic mutation or suppression of the pathway by non-genetic factors, is an important contributor to IPAH development.
Strategies to enhance BMPR-II signaling represent important and novel therapeutic opportunities to dampen or reverse pulmonary vascular remodeling.
An understanding of the mechanisms underpinning metabolic and inflammatory abnormalities in PAH has increased over recent years and has strengthened efforts to modify these abnormalities with drug treatments including small molecules targeting mitochondrial enzymes (e.g. dichloroacetate) and biologic agents targeting proinflammatory cytokines (e.g. tocilizumab).
Oxygen-sensing pathways are heavily implicated in PAH pathogenesis. Drugs that activate these pathways may be used long term in renal anemia, and the development of PAH as a potential complication should be considered.
Glossary
Anastrazole, a drug use to reduce conversion of androgens to estrogens. Idiopathic PAH was previously termed primary pulmonary hypertension and describes pre-capillary disease in the absence of conditions known to associate with the development of PAH or a family history of the disease.
Angioproliferative plexiform lesions
Mitochondrial-induced apoptosis. Mitochondrial membrane permeability is an important regulator of apoptosis and factors inducing mitochondrial dysfunction, loss of membrane potential and mitochondrial DNA damage can initiate this pathway.
Mixed venous hypoxemia refers to a relative reduction in the oxygen content of mixed venous blood with low levels indicating more severe disease in PAH.
Monocrotaline-induced PH.
Monocrotaline is a toxic plant alkaloid that induces PAH in rats over 2-3 weeks following injection, alongside an inflammatory response.
Paclitaxel is a chemotherapeutic agent that promotes microtubule stability and suppresses tumor cell proliferation.
Peroxisome proliferator-activated receptor- is a transcription factor with downstream targets involved in glucose homeostasis and vascular remodeling. Pre-capillary pulmonary hypertension is an elevation mean pulmonary arterial pressure (greater than 25 mmHg at rest) associated with a significant increase in pulmonary vascular resistance (greater than 3 Wood units) and in the absence of an elevated pulmonary artery wedge pressure (i.e. less than or equal to 15 mmHg). Postcapillary pulmonary hypertension is characterized by an elevated wedge pressure.
Proliferative vasculopathy. In pulmonary hypertension, small pulmonary arteries remodel through an imbalance of proliferation and apoptosis. All layers of the vessel are affected with key changes comprising intimal hyperplasia, medial hypertrophy and adventitial fibrosis.
Pulmonary arterial hypertension encompasses a group of conditions with a common hemodynamic phenotype of increased pulmonary arterial pressure and elevated pulmonary vascular resistance. Clinically the condition is characterized by progressive breathlessness, fatigue, syncope, right heart failure and premature death.
Pulmonary capillary hemangiomatosis is a rare cause of pulmonary hypertension, distinct from IPAH, and due to alveolar capillary proliferation.
Pulmonary vasoconstriction matches ventilation and perfusion in healthy lungs, but
PAH is characterized by sustained and severe vasoconstriction that contributes to the abnormal hemodynamic profile.
Pulmonary veno-occlusive disease occurs due to remodeling and occlusion of the pulmonary veins and venules and leads to severe and progressive pulmonary hypertension.
Rat models of pulmonary hypertension include the monocrotaline (MCT) and SUGEN/hypoxia (SuHx) models. SUGEN drug 5416, or SU5416, is VEGF receptor kinase inhibitor that induces endothelial cell apoptosis and, in combination with ambient hypoxia (10% oxygen), PAH develops over a 3-week period, with pulmonary vascular remodeling that resembles human pathology progressing over the proceeding 3-8
weeks.
Renal anemia occurs in the context of chronic kidney disease and is often treated by administration of erythropoietin (EPO). EPO is a HIF target gene and therefore inhibitors of PHD enzymes, that regulate HIF degradation, are in clinical trials to treat renal anemia.
Right ventricular systolic pressure (RVSP) is often reported in animal studies as it is not possible to advance the right heart catheter into the pulmonary artery to measure pulmonary arterial pressure.
SLC39A12 is the gene that encodes the zinc transporter, ZIP12.
SMAD proteins are a family of structurally related signaling proteins involved in BMP signaling.
Tacrolimus, or FK506, is a calcineurin inhibitor that is commonly used as an immunosuppressant following transplantation.
Tocilizumab is an anti-IL-6 antibody currently used in rheumatoid arthritis.
TopBP1 is the gene that encodes DNA topoisomerase 2-binding protein 1, a protein involved in DNA replication and repair.
Thromboembolic disease is an important cause of pulmonary hypertension that results from failure of thrombus resolution within the pulmonary circulation. Often patients will have a history of acute pulmonary embolism.
von-Hippel Lindau protein forms part of a ubiquitin ligase complex which ubiquitinates hydroxylated HIF-subunits, marking them for proteasomal destruction.
Whole exome sequencing is a strategy used to find variants in the coding region of genes. 
YAP/TAZ

